New drug aims to speed platelet recovery in blood cancer transplants

NCT ID NCT07321626

Recruiting now Disease control Sponsor: First Affiliated Hospital of Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called romiplostim N01 in 130 blood cancer patients receiving a stem cell transplant from a half-matched donor. The drug is given weekly for up to 4 weeks to help platelets recover faster, reducing the need for transfusions and bleeding risk. Half the patients get the drug, half get standard care, and researchers compare how quickly platelets return to safe levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Romiplostim N01 (a drug that boosts platelet production)
What this could lead to: If it works, this could help blood cancer patients recover platelets faster after a stem cell transplant, lowering the risk of dangerous bleeding.
What could go wrong: This is an early phase 1 trial with only 130 participants, so results may not apply to everyone. The drug could cause side effects like blood clots or not work better than standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia hematopoietic and lymphoid system neoplasm myelodysplastic syndrome myelodysplastic syndrome with excess blasts

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA DELAYED PLATELET ENGRAFTMENT HSCT MDS (MYELODYSPLASTIC SYNDROME)

Contacts and locations

Locations

The First Affiliated Hospital, College of Medicine, Zhejiang University
RECRUITING

Hangzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.